secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005420
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks
--------------------------------------------------------------------------------

- In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).
- NEK7 degradation ~80-90% in T cells across all dose levels (5-400 mg); favorable safety with mild/moderate AEs, no dose dependency.
- Median IL-6 dropped 55% to below cardiovascular risk threshold; CSF IL-6 decreased 75% in two subjects, suggesting CNS effect.
- Plan to initiate Phase 2 GFORCE-2 study in ASCVD in 2026; expand GFORCE-1 with readout H2 2026.
- Also evaluating Phase 2 studies in MASH, gout, recurrent pericarditis; collaborator Novartis to initiate Phase 2 studies of MRT-6160 in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/0001193125-26-005420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/glue-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer